• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Earnings Beat Might Change The Case For Investing In Exelixis Stock (EXEL)

    Simply Wall St·10/31/2026 23:31:16
    語音播報
    • Exelixis reported third quarter 2026 revenue of US$658.7 million and net income of US$218.1 million, with earnings per share from continuing operations above the prior year and management maintaining full year revenue guidance of US$2.5 billion to US$2.55 billion.
    • The oncology group continued to lean on its cabozantinib franchise while advancing multiple pivotal trials for zanzalintinib toward a planned March 2027 FDA decision in colorectal cancer, which keeps internal funding tied closely to execution in both the commercial and pipeline portfolios.
    • We will now look at how Exelixis' investment narrative could be shaped by this earnings beat and cabozantinib-driven performance.

    Scan how Exelixis' earnings story compares to other oncology and biotech plays by reviewing a curated group of 18 high quality undiscovered gems with strong fundamentals and room for a potential re-rating.

    What Is Exelixis' Investment Narrative?

    To own Exelixis, you need to be comfortable with a cancer-focused business that is highly dependent on cabozantinib cash flows while it spends heavily to build a second franchise around zanzalintinib. The Q3 beat and reaffirmed US$2.5b to US$2.55b revenue guidance indicate that current demand and pricing for CABOMETYX are funding that push. That keeps execution squarely in focus. The real near term swing factors remain the zanzalintinib pivotal readouts and the March 2027 FDA date for colorectal cancer, not this single quarter.

    In the shorter term, the earnings surprise, strong trailing returns and active buybacks highlight profitable operations, high return on equity and disciplined use of cash rather than aggressive external financing. That said, the share price is above some analyst targets, which suggests that higher expectations are already reflected in the valuation. The main operational risks now center on trial outcomes, regulatory timing and how Exelixis manages the cabozantinib lifecycle and competition while funding an expanding pipeline.

    Yet alongside the clean quarter and confident messaging, there is a less comfortable question around ...

    There's only one way to know the right time to buy, sell or hold Exelixis. Head to Simply Wall St's company report for the latest analysis of Exelixis's Fair Value.

    NasdaqGS:EXEL 1-Year Stock Price Chart
    NasdaqGS:EXEL 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternative angle around Exelixis focuses on regulatory and disclosure risk rather than the Q3 earnings beat. The most cautious analysts were assuming only about US$629 million of quarterly revenue and roughly US$212 million of net income back in Q2 2026, and still saw limited upside. Their more pessimistic story might shift after this report. It can therefore help to compare those older, lower expectations with your own view of the stock today.

    Explore 4 other Exelixis fair value estimates, including one that suggests as much as 17% downside from the current price.

    Decide For Yourself

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Exelixis research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • See our latest analysis for Exelixis. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Exelixis' overall financial health at a glance.

    Looking For More Investment Ideas Beyond Exelixis?

    Exelixis may already be on your watchlist, but portfolio returns often come from lining up a few different types of opportunities. The Simply Wall St Screener can help you quickly surface stocks that fit very specific criteria without wading through endless tickers on your own.